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ABSTRAK 
 
Latar Belakang. Bagi setiap pengumpulan darah dari mana-mana penderma darah 
yang berpotensi, pemeriksaan hemoglobin pra-pendermaan darah diperlukan. 
Penyaringan penderma berpotensi adalah penting bagi memastikan produk darah 
adalah selamat untuk penerima dan pada masa yang sama ia adalah selamat untuk 
penderma darah. Pemeriksaan hemoglobin dilakukan supaya penderma darah yang 
menpunyai tahap hemoglobin yang tidak normal tidak dibenarkan untuk menderma. 
Ini adalah untuk melindungi penderma darah dari kemerosotan kesihatan dan juga 
untuk melindungi kualiti komponen darah yang telah dikumpul.  Tujuan kajian ini 
adalah untuk menilai haemoglobinometer yang lebih baru untuk pemeriksaan 
hemoglobin di kalangan penderma darah di Pusat Darah Negara, Malaysia. 
 
 
Kaedah.  130 penderma darah yang layak di Pusat Darah Negara, Kuala Lumpur, 
Malaysia telah mengambil bahagian dalam kajian ini dari 1 Mac 2015 hingga 30 
September. Hemoglobin setiap penderma darah telah ditentukan oleh Compolab TM 
dan HemoCue HB301 melalui jari-cucuk ujian darah kapilari dan seterusnya darah 
vena di hantar ke makmal untuk ujian darah dengan menggunakan Sysmex XN-1000 
sebagai kaedah rujukan. Compolab TM dan HemoCue HB301 juga telah 
dibandingkan untuk kelajuan haemoglobinmeter. Kestabilan cuvettes yang telah 
dibuka pada 4  dan 7 bulan juga diuji. 
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Keputusan. Keputusan haemoglobin diambil dari 130 penderma darah yang layak. 
Purata hemoglobin bagi untuk Compolab TM, HemoCue HB301 dan Sysmex XN-
1000 hemoglobin adalah masing-masing 14.8, 14.70, 15.1 g/dL.  Analisis plot Bland 
Altman menunjukkan Compolab TM mempunyai bias yang lebih rendah (-0.37 g / 
dL) berbanding HemoCue (-0.44 g / dL) dan had sempit 95% limits of agreement 
yang lebih kecil.  Kedua-dua kaedah mempunyai kepekaan yang tinggi iaitu 96% 
untuk Compolab TM dan 100% untuk HemoCue HB301.  Ujian kebolehpercayaan 
dengan Intraclass correlation terhadap Sysmex XN-1000 adalah 0.993 untuk 
Compolab TM dan 0.996 untuk HemoCue, oleh itu, kedua-duanya adalah dianggap 
selamat untuk digunakan sebagai alat saringan hemoglobin.  Kepekaan untuk 
Compolab TM adalah tinggi tetapi HemoCue HB301 tidak boleh dikira. Compolab 
TM mempunyai lima subjek yang dilabel secara salah tidak layak dan satu subjek 
dilabel secara salah layak untuk menderma darah.  HemoCue HB301 mempunyai 
enam subjek yang dilabel secara salah tidak layak untuk pendermaan darah. Tiada 
perbezaan keputusan hemoglobin yang ketara apabila membandingkan cuvettes yang 
dibuka selama 4 bulan dan 7 bulan dengan cuvettes baru untuk Compolab TM dan 
HemoCue HB301. Compolab TM adalah lebih cepat daripada HemoCue HB301 
pada min 9.67 saat (P <0.001). 
 
Kesimpulan. Kedua-dua Compolab TM and HemoCue HB301 boleh digunapakai di 
dalam ujian saringan Hb pra-pendermaan. Prestasi Compolab TM juga adalah 
setanding dengan kaedah semasa, iaitu HemoCue HB301.  
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ABSTRACT 
Background. For every blood collection from any potential blood donor, pre-
transfusion haemoglobin screening is required. It is important to screen potential 
donors so that the blood products are safe for recipient and at the same time safe for 
the blood donor. Haemoglobin screening is performed so that blood donors with 
abnormal levels of haemoglobin are not allowed to donate.  This is to protect the 
donor from possible deterioration of health and also to protect the quality of the 
collected blood component.  The aim of this study was to evaluate a newer 
haemoglobinometer for haemoglobin screening among blood donors in National 
Blood Centre, Malaysia. 
 
Methods. 130 eligible blood donors in National Blood Centre, Kuala Lumpur, 
Malaysia participated in this study from 1st March 2015 to 30th September. Each 
blood donors’ Hb was determined by Compolab TM and HemoCue HB301 through 
finger-prick capillary blood test and subsequently laboratory venous blood test using 
Sysmex XN-1000 as the reference method.  Compolab TM and HemoCue HB301 
was also compared for haemoglobin measuring speed and stability of opened 
cuvettes at 4th and 7th months . 
 
Results. The Hb results were taken from 130 eligible blood donors. The mean Hb 
was 14.8, 14.70, 15.1 g/dL for Compolab TM, HemoCue HB301 and Sysmex XN-
1000, respectively. Bland Altman plot analysis showed Compolab TM had lower 
bias (-0.37 g/dL) as compared to HemoCue (-0.44 g/dL) and narrower 95% limits of 
agreement. Both methods for Compolab TM had high sensitivity at 96%and 
HemoCue HB301 at 100%.  Reliability with Intraclass correlation against Sysmex 
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XN-1000 was 0.993 for Compolab TM and 0.996 for HemoCue, therefore, both are 
considered safe to be use as screening tool. Specificity for Compolab TM was high 
but HemoCue HB301 was not calculable.  Compolab TM had five subjects which 
were falsely ineligible and one subject to be falsely eligible for blood donation.  
HemoCue HB301 had five subjects who were falsely eligible for blood donation.  
There were no significant differences in Hb results when comparing cuvettes that 
were opened for 4 months and 7 months with new cuvettes for Compolab TM and 
HemoCue HB301. Compolab TM was faster than HemoCue HB301 in detecting Hb 
reading at mean of 9.67 seconds (P<0.001).  
 
Conclusion. Both Compolab TM and HemoCue HB301 were reliable in measuring 
Hb level among blood donors. Performance of Compolab TM was comparable to 
current standard practice, which using HemoCue HB301. 
 1 
Chapter 1  
INTRODUCTION 
Overview 
For every blood collection from any potential blood donor, pre-transfusion 
haemoglobin (Hb) screening is required. It is important to screen potential donors so 
that the blood products are safe for recipient and at the same time safe for the blood 
donor. Hb screening is performed so that blood donors with abnormal levels of Hb 
are not allowed to donate.  This is to protect the donor from possible deterioration of 
health and also to protect the quality of the collected blood component (Roback et 
al., 2011). The acceptable value for pre-donation Hb is 12.5 g/dl – 18.0 g/dl in 
Malaysia (Ayob, 1998).   
 
In most blood donation settings, point of care (POC) devices are used instead 
of the larger haematology analyser that are present in haematology laboratories. This 
is because the machines are too large for transport to mobile donations sites. 
Capillary blood samples are commonly used in POC devices at blood donation 
settings for Hb screening because it is quicker and less hassle than using venous 
blood samples. In a study, capillary blood Hb level was higher than the venous blood 
levels by +0.3 g/dl but concluded that for potential blood donors, capillary or venous 
blood is equivalent to using a haematology analyser (Schalk et al., 2007). In other 
studies, POC devices analysing finger prick capillary blood samples are susceptible 
to larger differences from standard laboratory measurements which using venous 
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blood sample, with differences up to 1.2 to 1.8 g/dl from reference standards 
(Gehring et al., 2002; Gómez-Simón et al., 2007; Patel et al., 2007).  Therefore, 
there is a need for newer POC devices that can decrease the differences when 
compared with reference standards. 
 
In the National Blood Centre (PDN) in Kuala Lumpur, the common Hb 
screening for pre-blood donation is measured by using finger prick sampling of 
capillary blood either subjectively by Copper Sulphate method or quantitatively by 
HemoCue HB301. While the copper sulphate method may be quick and cost 
effective screening tool, it can produce the highest donor acceptance despite 
unacceptable Hb levels for donation (Gómez-Simón et al., 2007).  The HemoCue 
Blood Hb haemoglobinometer is the second line of test if the copper sulphate method 
shows the donor's Hb level to be below the acceptable limit of 12.5 g/dl in PDN 
(Khor et al., 2010).  HemoCue has been used commercially for some years and has 
been reported to be reasonably reliable (Bahadur et al., 2010, Seguin et al., 2011).  
Despite HemoCue popularity worldwide, there is still conflicting reports of its 
accuracy (Patel et al., 2013, Bahadur et al., 2010).  The HemoCue Blood Hb 
haemoglobinometer display readings at only after approximately 10 seconds which 
may contribute to delays in the screening process especially during mobiles and the 
sample volume used in each test is 10 µl. The HemoCue haemoglobinometer's 
cuvette has expiration date for unopened cuvettes of 2 years but when opened it is 
only stable for 3 months.  
 
The CompoLab TM system in this study can measure instantly at 1-2 seconds 
and uses only 10 µl of blood sample volume. The cuvettes used in this system have 
 3 
an expiration date of opened cuvettes of 2.5 years. Similarly, the cuvettes do not 
contain any reagent for processing Hb levels. This study is carried out to assess the 
suitability of using this system for Hb screening at blood donation settings and to 
find a faster, cheaper and reliable instrument as an alternative to the current 
haemoglobinometer system used. 
 
Research Justification 
CompoLab TM haemoglobinometer will provide rapid result and will be easy 
to operate. It has a shorter timeframe (1-2secs) to process results compared to the 
current HemoCue haemoglobinometer (approximately 10 secs) used in National 
Blood Centre. In comparison, the HemoCue haemoglobinometer system's cuvettes 
have an expiry date of 3 months after opening its packaging compared to the 
CompoLab TM haemoglobinometer system's cuvettes which lasts for 2.5 year even 
after opening its packaging.  
 
The National Blood Centre usually deal with high volume of blood donors. 
Thus, the centres requires reliable, accurate, rapid and cost effective portable 
haemoglobinometer for Hb level screening. This study is to justify the possible 
savings in costs and time of the CompoLab TM haemoglobinometer system 
compared to the HemoCue haemoglobinometer system. 
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Research Objectives 
1.1.1 General Objective 
 To compare the CompoLab TM system to HemoCue haemoglobinometer 
system as a Hb screening tool in blood donation setting. 
 
1.1.2 Specific Objectives 
 
i. To determine the reliability of CompoLab TM haemoglobinometer 
system  and HemoCue haemoglobinometer system in measuring Hb level 
among blood donors against the gold standard method (Sodium lauryl 
sulphate Method).   
 
ii. To compare the measuring speed of CompoLab TM haemoglobinometer 
system in measuring Hb level among blood donor against HemoCue. 
 
iii. To determine the cuvette time stability of CompoLab TM and HemoCue 
HB301 haemoglobinometer system in measuring Hb level among blood. 
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Hypothesis  
 
i. CompoLab TM haemoglobinometer system and HemoCue are reliable 
in measuring Hb level among blood donors against the gold standard 
method (Sodium lauryl sulphate Method).  
 
ii. CompoLab TM haemoglobinometer system is as reliable as HemoCue 
in measuring Hb level among blood donors. 
 
iii. CompoLab TM haemoglobinometer system is faster than HemoCue in 
measuring Hb level among blood donors. 
 
iv. CompoLab TM haemoglobinometer system has equally good time 
stable cuvettes than HemoCue in measuring Hb level among blood 
donors. 
 
 
Study Endpoints 
Primary Endpoint: To determine the  reliability of the CompoLab TM 
haemoglobinometer system compared to the HemoCue haemoglobinometer system 
when testing donors blood haemoglobin level.
 6 
Chapter 2  
LITERATURE REVIEW 
Introduction 
Blood transfusion has its place in modern medicine and over time it has 
become indispensible. Blood product usage has increase in modern medicine partly 
due to the  increasing population and also the rise of accidents that require blood 
transfusion. Surgeries and diseases that require blood transfusion support pushes 
blood transfusion services to cope with the increasing demand of blood(Abolghasemi 
et al., 2010). The blood transfusion service needs to retain as much as possible 
existing regular blood donors and recruit new blood donors.  Blood transfusion 
services are also required to look after the health of their blood donors by monitoring 
their iron storage status especially for long term regular donors(Lynch et al, 2004).  
Blood transfusion service should have proper protocols adhered for vigilance 
towards their blood products to ensure safe and quality products are produced. 
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Blood Donation Process 
2.1.1 Donor Criteria 
Blood donors are required to fulfil blood donor criteria based on the blood 
donors' medical history, travel history, sexual history, family history, general 
examination, blood pressure and body weight.  Another important aspect is that the 
blood donors must not be remunerated for their blood donation as stated by the 
World Health Organisation (WHO).  This is to ensure blood donors are safe 
donors(Ayob,1998). 
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2.1.2 Work flow for whole blood donation  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Refreshment 
 
 Donor Registration Form 
Registration 
Measure Bodyweight 
Check blood grouping 
  
Haemoglobin test 
Pre-Donation interview 
 
Blood Pressure test 
Eligible: blood donation Ineligible: defer 
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Deferral of blood donors 
 
Based on the donor criteria, a blood donor can be deferred temporarily or 
pemanently. Examples of the cause of temporary deferral are like low haemoglobin 
level , high or low blood pressure, recent infection or lack of sleep. When the blood 
donor is temporarily deferred, the deferment period can be from one day to a few 
years depending on the reason of the deferral. Low haemoglobin value is the most 
common cause of blood donor deferral worldwide, particularly among women 
(Goncalez et al., 2013; Ngoma et al., 2013; Popovsky, 2012; Prados Madrona et al., 
2014; Smith et al., 2013). Low haemoglobin is also the main cause of temporary 
blood donor deferral in National Blood Centre Kuala Lumpur followed by high 
blood pressure (BP), blood donors on medication, and low blood pressure. Each year 
around ten thousand of blood donor, estimated five to six percent of total blood 
donors were deferred due to low Hb.(Donor Procurement unit, 2014a)  
When a blood donor is permanently deferred it means  the deferred donor can 
no longer participate in blood donation for life. Examples of permanent deferral are 
blood donors who are at high risk of contracting sexually transmitted diseases(STI), 
intravenous drug users(IVDU), family history of hepatitis B infection or history of 
epilepsy(Ayob,1998). 
In Malaysia, blood donors should have the minimum requirement for Hb 
level of 12.5 g/dL for male and female(Ayob,1998). Some countries might have 
different minimum requirements, for example 12.5 g/dL for female and 13.5 g/dL in 
Europe, while in Japan 12.0 g/dL for 200 mL blood bag and 12.5 g/dL for 400 mL 
blood bag but in the USA the minimum Hb level is similar to Malaysia (Gómez-
Simón et al., 2007).  
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Return to Donate 
 
Blood donor deferral may discourage donors to return for blood donation.  
Deferral due to low Hb can cause the loss of potential blood donors and also lead to 
shortage of blood supply (Hillgrove et al., 2011). This would most likely occur to 
first time donors as compared to the regular and repeat donors. There was a  5 year 
follow-up study that showed that 25 percent of first time blood donors who were 
temporarily deferred returned to donate and 47 percent first time eligible donors 
returned. The study also showed that repeat donors who were previously temporarily 
deferred had 81 percent return to donate whereas those who previously eligible 
donors 86 percent return to donate (Custer et al., 2007).  The study showed the 
importance of repeat donors who were more likely to donate and other factors like 
age, sex, race, and education level were linked with the return of donors (Custer et 
al., 2007; Custer et al., 2011; Zou et al., 2008).  A local study done at National 
Blood Centre showed that only 26.6% of the blood donors returned to donate within 
7 months after being deferred (Siti Suzaina, 2013).  The study also showed that 
repeat donors were more likely to return to donate with a return percentage of 90%.  
The reasons were some of the blood donors were afraid of being re-deferred (17.6%), 
too busy to donate (30.1%), pregnancy and having new medical illness.  
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Adverse Donor Reaction  
 
The blood donation process is usually uneventful and rarely blood donors 
will suffer any adverse reaction due to blood donation but occasionally there would 
be exceptions.  Data from donor vigilance National Blood Centre showed that 
vasovagal reaction is the most common adverse donor reaction. 171 donors suffered 
from vasovagal reaction in the first 6 month of 2013 and rose to 383 for the same 
period in 2014.  The affected blood donors in 2013 who returned for blood donation 
was only 20.5% until end of October 2014 (Donor Procurement Unit, 2014b). Fear 
may be one of the commonest reasons that leads to adverse donor reaction (Oswalt, 
1977). With the sight of blood, fear of needles or the fear of pain are few causes that 
may cause vasovagal reaction.  The reaction may occur before venepuncture and 
others may have delayed presentation.  Vasovagal reaction due to hypotension post 
blood donation is also one of the commonest reason. The adverse reactions can range 
from mild vasovagal reaction like light headedness, pallor and sweating to severe 
form of reaction like convulsive syncope and loss of consciousness. These can lead 
to serious accidental injuries like head injuries from fall or motor vehicle accidents if 
the blood donor was operating a vehicle when vasovagal attack occurs. Younger age, 
female gender, and first time donation are known risk factor of adverse donor 
reaction (Goldman et al., 2013).  Optimizing water intake has been suggested in a 
study to mitigate vasovagal reaction in which the blood donor was requested to 
ingest 500 ml of water prior to blood donation (Wieling et al., 2011).  It was noted  
that after drinking water, the healthy young subjects had improved orthostatic 
tolerance. The study also suggested 250 ml of sports drink or salt supplementation in 
oral fluids prior to blood donation will also mitigate adverse vasovagal reactions.    
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Haemoglobin 
 
Haemoglobin is the most important and also the most abundant molecule in 
the red blood cells, approximately about 270,000,000 Hb molecules per red blood 
cells. It consists of two pairs of polypeptide chains (globins) and four-heme 
molecules with a ferrous iron inside each. It main function is as a carrier for oxygen 
(O2) and carbon dioxide (CO2). Each gram of Hb can hold up to maximum of 1.34 
mL of O2 (McPherson and Pincus, 2011). Since the O2 is the vital component of 
human life, the measurement of O2 and its carrier, which is Hb are the most routine 
laboratory investigations in healthcare systems. The Hb is measured in gram per 
deciliter (g/dL).   Table 2.1 showed the variation of Hb according to gender in a 
multiethnic population. 
 
 
Table 2.1 Haematological parameters of a multiethnic population.(Ambayya et al., 
2014) 
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Principle of Haemoglobin Measurement 
 
International Council for Standardisation in Haematology (ICSH) has 
determined a few methods of measuring haemoglobin concentrations. The 
haemiglobincyanide (HiCN) method was approved in 1995 as the reference method 
for haemoglobinometry in human blood. The HiCN method is currently the gold 
standard  reference for Hb value measurement. Any new methods will need to 
compare with the HiCN method as the reference Hb value. (Zwart et al., 1996) 
 
HiCN (cyanmethhaemoglobin) is converted from haemoglobin lysed through 
a chemical process using reagents; potassium ferricyanide and potassium cyanide 
(Drabkin’s reagent). Haemoglobin is converted into methaemoglobin by the 
oxidizing process of potassium ferricyanide.  HiCN is formed after the Hi binds to 
cyanide ions from potassium cyanide.  HiCN is a form of Hb pigment that can be 
measured by using a spectrophotometer. Examples of Hb pigments that can be 
measured with a spectrophotometer are shown in Figure 2.1 and Table 2.2. HiCN has 
a broad absorption maximum wavelength at about 540 nm which minimizes bias 
error.  The HiCN method has a stable standard solution which is stable up to 15 years 
and approved by ICSH as a standard international reference for Hb concentration 
level.  The HiCN method is able to measure other forms of Hb pigments like 
Oxyhaemoglobin (HbO2), Methaemoglobin (Hi), and Carboxyhaemoglobin (HbCO)  
but not Sulfhaemoglobin (SHb) (Lewis et al., 1991; McPherson and Pincus, 2011). 
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Figure 2.1 Absorption spectra of different form of Haemoglobin pigments. HbCO, 
carboxyhaemoglobin; HbO2, oxyhaemoglobin; SHb, sulphaemoglobin; Hi, 
methaemoglobin (Dacie and Lewis, 2012) 
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Table 2.2 Absorption spectra of different form of Haemoglobin pigments. (Dacie and 
Lewis, 2012) 
 
Formation of oxyhaemoglobin (HbO2) occurs when each heme group is 
bound with one molecule of O2. Methaemoglobin (Hi) is formed when ferrous iron in 
the heme group is in the ferric iron state, restricting methaemoglobin to bind with O2.  
Formation of Carboxyhaemoglobin (HbCO) occurs when Hb binds with carbon 
monoxide (CO) and this form of haemoglobin is unable to bind with O2 due to CO 
affinity is 200 times greater than O2 toward Hb, which impairs the oxygen carrying 
capacity of Hb. Sulphaemoglobin (SHb) is formed during oxidative hemolysis and 
contained a mixture of partially denatured Hb (McPherson and Pincus, 2011).  
 
Unfortunately, the reagents that the HiCN methods use contains potassium 
cyanide and it is toxic to the environment and laboratory personnel especially at high 
concentration (Shah et al., 2011). The safe disposal of this reagent is troublesome 
especially when large volumes of laboratory waste contains cyanide.  There are 
alternative non-hazardous reagents available like sodium azide, sodium lauryl 
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sulphate, imidazole, sodium dodecyl sulphate and dimethyl lauryl amine oxide which 
are safer and do not contain hazardous waste. These reagents have been validated 
and are used in laboratories (Lewis et al., 1991). The reagents work almost similarly 
to the HiCN method; for example sodium lauryl sulphate Method (SLS) will convert 
the haemoglobin to haemiglobinsulphate almost immediately and the absorbance is 
read by using spectrophotometer at 534nm maximum absorbance wavelength. It is 
stable for several days without significant effect of storage. Its reliability is equal to 
that of haemiglobincyanide method with routine blood specimens, slightly more 
reliable when there is interference by leucocytosis or lipaemia. There is no 
significant difference in measurements on samples containing Hb F. It measures 
methaemoglobin but fails to measure sulphaemoglobin. It has a major advantage in 
that the reagent is a non-hazardous compound(Lewis et al., 1991).  The 
oxyhaemoglobin (HbO2) method is the fastest method among all the other methods. 
The dilution reagent contains ammonia and the absorbance of the final solution is 
read by spectrophotometer at 540 nm wavelength (Barbara et al., 2011). The 
disadvantage of current alternatives to HiCN method is the unavailability of stable 
standards; therefore, the calibration is done by using HiCN reference solutions(Zwart 
et al., 1996). 
 
 Most of the automated haematology analysers are using the above-mentioned 
method. It produces accurate and reliable Hb value. Sysmex XN-1000 that was used 
in this research measure the haemoglobin value by the Sodium lauryl sulphate (SLS) 
method.  
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It is common that point of care (POC) haemoglobinometers uses 
spectrophotometry in haemoglobin concentration measurements. The 
haemoglobinometer uses a factory pre-calibrated spectrophotometer that is based on 
ICSH HiCN standard. The HemoCue 201 (HemoCue AB, Angelsholm, Sweden) for 
example uses the direct spectrophotometry method and uses cuvette that has been 
pre-filled with reagent (sodium nitrite and sodium azide). It converts haemoglobin 
into azidemethaemoglobin, and the spectrophotometer measures the absorbance 
wavelength of the azidemethaemoglobin at 565 and 880 nm. The disadvantage of 
HemoCue 201 is the disposable reagent pre-filled cuvettes are expensive and the 
reagent in the cuvettes deteriorates under suboptimal environmental 
conditions(Morris et al., 2007).  
 
In this study, HemoCue HB301 uses the Hb/HbO2 isobestic point absorbance 
method that utilizes reagent-free microcuvettes. This microcuvettes is quite robust as 
it can be stored unopened at 10 – 40 °C until expiration date; short-term storage (six 
weeks) at -18 – 50 °C; and 3 months open vial stability based on a previous 
study(Morris et al., 2007) but latest specification from HemoCue America shows 
stability up to 12 months(HemoCue America, 2014).  The analyzer uses a double 
wavelength measuring method at 506 nm and 880 nm(Morris et al., 2007).  As for 
Compolab TM, it is calibrated according to ICSH Photometric method with broad 
spectrum wavelengths and also uses the similar Hb/HbO2 isobestic point absorbance 
method. It measures Hb level in less than 2 seconds and has a measuring rage of 0.3-
25.5 g/dL. Its cuvettes are reagent-free and can be stored at 0 - 50 °C up to 2.5 years 
or -30 - 70°C up to 24 hours even after the cuvette bag has been 
opened(Fresinius,2013).   
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In poor countries there is a much cheaper  methods of measuring 
haemoglobin.  The Haemoglobin Colour Scale (HCS) which is licensed by the World 
Health Organization (WHO) was released to the public in 2001 and each test only 
cost less than USD0.05. The Hb value is derived by comparison of the colour of a 
drop of blood with the set of printed colour shades representing Hb values between 4 
to 14 g/dL with 2 g/dL increments (World Health Organization, 2004).  The only 
disadvantage is that is when reading the haemoglobin result, errors can occur due to 
poor lighting  and then the test requires time for the blood to dry out on the test paper 
matrix before it can be read.  There was a study which used HCS as one of its 
haemoglobin screening methods and it showed 25.2% incorrect haemoglobin 
estimation (Tondon et al., 2009).  
 
Copper Sulphate solution (CuSO4) is another low cost method to measure Hb 
concentration by the gravimetry principle and then determines the haemoglobin level 
semi-quantitatively (Philipps et al., 1950). With the known specific gravity for the 
solution, the CuSO4 solution can be prepared in house at the blood transfusion 
service centre.  If the CuSO4  is prepared with a specific gravity of 1.053, it is able to 
measure haemoglobin level which is equivalent to the value of 12.5 g/dL.  A drop of 
whole blood is dropped into the solution and then the CuSO4 will form a layer of 
copper proteinate around the drop of blood. This will maintain the drop of blood's 
specific gravity for 15-20 seconds. The haemoglobin value is known by observing 
whether the drop of blood floats or sinks in the solution. If the drop of blood sinks, 
the haemoglobin level is more than 12.5 g/dL .  If it stays afloat then the 
haemoglobin level is either at 12.5 g/dL or less.  This method is commonly used in 
blood donation mobiles or centres because it is cheap, relatively easy to perform and 
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provide rapid results.  Unfortunately, this method requires proper technical 
knowledge to prepare the solution.  There is a very narrow margin of error when 
preparing the solution, and any error can give a wrong results.  Blood donation 
service centres must be careful when using this method at their centres (Deb et al., 
2002).  If a blood donor is tested with the CuSO4 method and fails, they will usually 
undergo a second test with a POC haemoglobinometer like the HemoCue (James et 
al., 2003). 
There  are other newer alternative technology which may help to reduce cost 
of pre-donation haemoglobin screening which is by non-invasive haemoglobin 
screening method. This method is similar to the principle of pulse oximeter that 
measures the Oxygen saturation in the blood (SpO2). These non-invasive 
haemoglobinometers do not require cuvettes or the need for finger pricking 
equipment.  However, these haemoglobinometer requires a large initial cost outlay 
and may be prohibitive to poorer blood transfusion centres.   The operating costs for 
predonation screening can be reduced if the centres are able to bear the initial costs. 
There are three non-invasive haemoglobinometer devices that are currently available 
in the market.  The three devices are Haemospect (MBR Optical Systems GmbH & 
Co. KG, Germany), NBM-200 (OrSense, Israel) and products from Masimo, USA; 
Radical-7, Rad-87, Rad-57, Pronto-7 and Pronto.  The non-invasive 
haemoglobinometers are based on transcutaneous reflection spectroscopy method. It 
projects a white light into the skin and underlying tissues, then the reflected 
transmission data will be captured and analysed.  Some use  an occlusion 
spectrophotometer-based haemoglobinometer monitor which create blood dynamics 
in which will generate an optical signal to analyse haemoglobin value.   
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Blood Sampling for Haemoglobin Measurement Test 
 
Capillary blood sample for haemoglobin (Hb) determination is preferred than 
venous blood sample in blood donation setting due to ease of sample collection. A 
study regarding the use of capillary blood count parameters in adults showed 
capillary Hb was higher than the venous values (+0.30 g/dL), however they 
concluded that for potential blood donors, Hb screening is equivalent with either 
capillary or venous blood using a haematology analyser (Schalk et al., 2007). During 
the predonation Hb screening, if there is a need for a repeat test from the same 
fingerpick due to borderline prerequisite blood donation Hb level; a faster point of 
care (POC) haemoglobinometer would be better to prevent the process of 
haemostasis from affecting the Hb level result. 
 
Haemoglobin Measurement Devices 
 
In blood donation setting, Point of Care (POC) devices is used instead of 
automated haematology analyser due to mobility factor as the latter is too big and 
heavy whereas the former is small and light handheld device. Apart from that, the 
cost and maintenance of POC devices is much cheaper compare to the automated 
haematology analyser. POC devices usually have reduced accuracy when compared 
with haematology analyzer and some haemoglobinometers require quality control 
reagent however, with newer technologies coming into the market, this has changed. 
Several studies show that results from POC devices which analysed finger prick 
capillary blood when compared to results from standard laboratory measurements 
